Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04268498 · ClinicalTrials.gov registry record · Phase 2

A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma

A Phase 2 study of Multiple Myeloma, sponsored by University of Miami.

Active
Registry status
Phase 2
Development phase
310
Enrollment target
7
Study locations

NCT04268498 is a Phase 2 study of Multiple Myeloma that is active but no longer recruiting, run by University of Miami. The registered enrollment target is 310 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (43% lower). The trial reports 7 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04268498, a Phase 2 study of Multiple Myeloma, is active but no longer recruiting, sponsored by University of Miami.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
310 participants
Enrollment target
7
Study locations

Study Summary

This study is being done to find out whether carfilzomib, lenalidomide, and dexamethasone (KRD) or KRD and Daratumumab (KRD+DARA) might be safer and more effective ways of controlling multiple myeloma than the standard of care treatment, which is lenalidomide, bortezomib, and dexamethasone (VRD).

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG Acetaminophen
  • DRUG Dexamethasone
  • DRUG Lenalidomide
  • DRUG Diphenhydramine
  • DRUG Bortezomib

Study Locations (7)

New York

  • Roswell Park Comprehensive Cancer Center - Buffalo
  • Memorial Sloan Kettering Cancer Center - New York
  • Stony Brook University - Stony Brook

Florida

  • University of Miami - Miami
  • Moffitt Cancer Center - Tampa

Texas

  • MD Anderson Cancer Center - Houston

Utah

  • Huntsman Cancer Institue - Salt Lake City

Trial Details

FieldValue
Enrollment Target 310 participants
Start Date 2020-02-11
Est. Completion 2027-02-01
Phase Phase 2

Sponsor

University of Miami

721 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04268498

The ClinicalTrials.gov registry entry for NCT04268498 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 310 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (43% lower). The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Acetaminophen is the first listed.

NCT04268498 reports 7 study locations spanning 4 distinct geographic areas - top geographies include New York, Florida, Texas.

Frequently Asked Questions

What is clinical trial NCT04268498 about?

NCT04268498 is a clinical study titled "A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma". This study is being done to find out whether carfilzomib, lenalidomide, and dexamethasone (KRD) or KRD and Daratumumab (KRD+DARA) might be safer and more effective ways of controlling multiple myeloma than the standard of care treatment, which is lenalidomide, bortezomib, and dexamethasone (VRD).

What is the current status of trial NCT04268498?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 310 participants. The study started on 2020-02-11. Estimated completion is 2027-02-01.

What conditions does trial NCT04268498 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT04268498?

The interventions under investigation include: Acetaminophen (DRUG), Dexamethasone (DRUG), Lenalidomide (DRUG), Diphenhydramine (DRUG), Bortezomib (DRUG).

Who is sponsoring clinical trial NCT04268498?

This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04268498 being conducted?

This trial has 7 study locations across Florida, New York, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.